Trials / Completed
CompletedNCT01069003
EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy (DAPT) Drug Regimen
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,272 (actual)
- Sponsor
- Medtronic Vascular · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and aspirin as part of a dual antiplatelet therapy (DAPT) drug regimen.
Detailed description
To provide clinical information on rates of late and very late stent thrombosis after Endeavor Drug-eluting Stent (DES)placement in an all comers population with a broad range of bleeding and thrombosis risk. EDUCATE will further analyze the current practice of clinicians regarding temporary cessation of antiplatelet therapy and its association with clinical outcomes. In addition, patients included in this broad Endeavor registry will also be contributed to the DAPT native study population for analysis of 12 vs 30 months duration of dual antiplatelet therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo Arm | Placebo and ASA (75 mg - 325 mg) |
| DRUG | Thienopyridine Therapy | Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg) |
| DEVICE | Surveillance Arm | Non randomized arm to understand clinical outcomes in a commercial setting |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2010-02-17
- Last updated
- 2016-01-20
- Results posted
- 2016-01-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01069003. Inclusion in this directory is not an endorsement.